Related references
Note: Only part of the references are listed.Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk
Deborah Grady et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Estrogen therapy and coronary-artery calcification
JoAnn E. Manson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Jacques E. Rossouw et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
One-year cardiovascular event rates in outpatients with atherothrombosis
Ph. Gabriel Steg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
Elizabeth Barrett-Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Re: Combined postmenopausal hormone therapy and cardiovascular disease: Toward resolving the discrepancy between observational studies and the women's health initiative clinical trial
WC Willett et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation
F Grodstein et al.
JOURNAL OF WOMENS HEALTH (2006)
Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx
FP Leung et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
Molecular and cellular basis of cardiovascular gender differences
ME Mendelsohn et al.
SCIENCE (2005)
Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current
R Liew et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial
GL Anderson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Continuing outcomes relevant to evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
S Martino et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Cardiovascular effects of raloxifene: The arterial and venous systems
RS Blumenthal et al.
AMERICAN HEART JOURNAL (2004)
Estrogen plus progestin and the risk of coronary heart disease
JE Manson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial
NK Wenger et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd et al.
LANCET (2002)
Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice
ME Rosenfeld et al.
ATHEROSCLEROSIS (2002)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
JE Rossouw et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Design and methods of the raloxifene use for the heart (RUTH) study
L Mosca et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Share Paper
